abs284.txt	although	great	success	has	been	obtained	in	the	clinic		the	current	immunecheckpoint	inhibitors	still	face	two	challenging	problems		low	response	rate	andimmune-related	adverse	effects	(iraes)		here	we	report	the	combination	ofimmunogenic	chemotherapy	and	locally	expressed	pd-l1	trap	fusion	protein	forefficacious	and	safe	cancer	immunotherapy		we	demonstrate	that	oxaliplatin	(oxp)boosts	anti-pd-l1	mab	therapy	against	murine	colorectal	cancer		by	design	of	apd-l1	trap	and	loading	its	coding	plasmid	dna	into	a	lipid-protamine-dnananoparticle		pd-l1	trap	is	produced	transiently	and	locally	in	the	tumormicroenvironment		and	synergizes	with	oxp	for	tumor	inhibition		significantly	unlike	the	combination	of	oxp	and	anti-pd-l1	mab		the	combination	of	oxp	andpd-l1	trap	does	not	induce	obvious	th17	cells	accumulation	in	the	spleen	indicating	better	tolerance	and	lower	tendency	to	iraes		the	reports	here	mayhighlight	the	potential	of	applying	pd-l1	inhibitor		especially	locally	expressedpd-l1	trap		in	cancer	therapy	following	oxp-based	chemotherapy	
